Direkt zum Inhalt
Merck
  • Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with Trans-retinoic acid.

Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with Trans-retinoic acid.

BMC neuroscience (2013-04-20)
Devon Andres, Brian M Keyser, John Petrali, Betty Benton, Kyle S Hubbard, Patrick M McNutt, Radharaman Ray
ZUSAMMENFASSUNG

Immortalized neuronal cell lines can be induced to differentiate into more mature neurons by adding specific compounds or growth factors to the culture medium. This property makes neuronal cell lines attractive as in vitro cell models to study neuronal functions and neurotoxicity. The clonal human neuroblastoma BE(2)-M17 cell line is known to differentiate into a more prominent neuronal cell type by treatment with trans-retinoic acid. However, there is a lack of information on the morphological and functional aspects of these differentiated cells. We studied the effects of trans-retinoic acid treatment on (a) some differentiation marker proteins, (b) types of voltage-gated calcium (Ca2+) channels and (c) Ca2+-dependent neurotransmitter ([3H] glycine) release in cultured BE(2)-M17 cells. Cells treated with 10 μM trans-retinoic acid (RA) for 72 hrs exhibited marked changes in morphology to include neurite extensions; presence of P/Q, N and T-type voltage-gated Ca2+ channels; and expression of neuron specific enolase (NSE), synaptosomal-associated protein 25 (SNAP-25), nicotinic acetylcholine receptor α7 (nAChR-α7) and other neuronal markers. Moreover, retinoic acid treated cells had a significant increase in evoked Ca2+-dependent neurotransmitter release capacity. In toxicity studies of the toxic gas, phosgene (CG), that differentiation of M17 cells with RA was required to see the changes in intracellular free Ca2+ concentrations following exposure to CG. Taken together, retinoic acid treated cells had improved morphological features as well as neuronal characteristics and functions; thus, these retinoic acid differentiated BE(2)-M17 cells may serve as a better neuronal model to study neurobiology and/or neurotoxicity.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Kaliumchlorid, ACS reagent, 99.0-100.5%
Sigma-Aldrich
Proteasehemmer-Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
Glycin, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glycin, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Glycin, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Kaliumchlorid, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E508, 99-100.5% (AT), ≤0.0001% Al
Sigma-Aldrich
Kaliumchlorid, ≥99.0%
Sigma-Aldrich
Kalzium-Ionophor A23187, ≥98% (TLC), powder
Sigma-Aldrich
Kaliumchlorid, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99.0%
Sigma-Aldrich
Kaliumchlorid, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Glycin, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Kaliumchlorid -Lösung, BioUltra, ~1 M in H2O
SAFC
Glycin
Sigma-Aldrich
Glycin -hydrochlorid, ≥99% (HPLC)
Sigma-Aldrich
Kaliumchlorid, puriss. p.a., ≥99.5% (AT)
Sigma-Aldrich
Kaliumchlorid, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
Kaliumchlorid, 99.999% trace metals basis
Sigma-Aldrich
Phosgen -Lösung, 15 wt. % in toluene
Sigma-Aldrich
Glycin, BioXtra, ≥99% (titration)
Sigma-Aldrich
Phosgen -Lösung, ~20% in toluene
Sigma-Aldrich
Glycin 1 M -Lösung
Sigma-Aldrich
Anti-Synapsin I-Antikörper, serum, Chemicon®
Sigma-Aldrich
Glycin, 99%, FCC
Sigma-Aldrich
Kaliumchlorid, ≥99.99% trace metals basis
Sigma-Aldrich
Monoclonal Anti-Vimentin antibody produced in mouse, clone LN-6, ascites fluid
Supelco
Potassium chloride -Lösung, ~3 M KCl, saturated with silver chloride
Sigma-Aldrich
Kaliumchlorid, BioXtra, ≥99.0%
Sigma-Aldrich
Glycin, ACS reagent, ≥98.5%
Supelco
ISA (Ionenstärke-Einstellreagens: 1 M KCl), 1 M KCl
Sigma-Aldrich
Kaliumchlorid, AnhydroBeads, −10 mesh, 99.999% trace metals basis